Study of PHA-848125AC in Adult Patients With Advanced/Metastatic Solid Tumors

Summary

The purpose of this open-label, multi center, Phase I study was to determine the safety profile of the oral compound PHA-848125AC administered according to two different schedules of administrations to advanced/metastatic solid tumor patients. Objectives of the study were to determine the maximum tolerated dose and the dose that can be recommended for Phase II investigations.

Timeline

Start

2006-04

Primary completion

2009-05

Completion

2009-12

Drugs

Indications